MediGene: European Approval Procedure for the Six-Months Dosage of Cancer Drug Eligard® Successfully Completed

Martinsried/Munich, August 31, 2007. MediGene AG (Frankfurt, Prime Standard: MDG) announces that the European approval procedure for the six-month dosage of Eligard® was successfully completed. As soon as this positive decision has been implemented in the individual countries, this dosage of the drug for the treatment of prostate cancer can be launched in Europe. In Germany, the six-month dosage has been successful since March 2007. After subcutaneous injection of this dosage, the drug is released steadily over a period of six months. Eligard® is the only six-month depot product of a drug against prostate cancer available in Europe. The one-month and three-month products have been available in all major European countries. The drug is marketed by MediGene's licensee Astellas Pharma Europe Ltd. MediGene expects that the Eligard® revenue will meet the target projected for 2007. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: "The six-month dosage of Eligard® represents a further improvement in patient management. There has been tremendous response since the launch of the Eligard 6 month formulation earlier this year in Germany. We are now glad that we can offer this 6 month dosage to patients across Europe." MediGene acquired the licence for pan-European commercialization of Eligard® from the US Company Atrix Laboratories, Inc. (today's QLT Inc., USA) in April 2001, and successfully took the drug through the approval procedure, first of all in Germany, and afterwards, in cooperation with Astellas in Europe. Eligard® has been marketed in Europe by MediGene's licensee Astellas Pharma Europe Ltd since May 2004. The six-month dosage (45 mgs) was launched in Germany in March 2007. Other available formulations of Eligard include the one-month (7.5 mgs), and three-month (22.5 mgs) depot products. Eligard® is the first product of MediGene's broad drug pipeline that has been available on the European market. Another drug, the Polyphenon® E Ointment, was approved for marketing by the US regulatory authority FDA, and the third drug, Oracea®, is currently undergoing approval procedures in Europe. In addition, MediGene has drug candidates for the treatment of cancer and autoimmune diseases in clinical development, and possesses several innovative platform technologies, i.e. EndoTAG®, HSV, and mTCRs (soluble T-cell receptors). About Eligard®: Eligard® is a LH-RH agonist (LH-RH = luteinizing hormone-releasing hormone) which significantly and consistently reduces the testosterone level in the body, thus suppressing tumour growth in patients suffering from advanced, hormone-dependent prostate cancer. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM and EndoTAGTM-1are trademarks of MediGene AG, RhuDex® is a trademark of MediGene Ltd., Polyphenon® is a trademark of Mitsui-Norin, Eligard® is a trademark of QLT, Inc. - ends - MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. Another drug obtained marketing authorization for the USA, two drug candidates are currently undergoing the European approval procedures. Furthermore MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development. Contact MediGene AG: Email: Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946 --- End of Message --- MediGene AG Lochhamer Strasse 11 Martinsried / München Germany WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;